Gilead Sciences Announces First Quarter 2024 Financial Results

25.04.2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, ...

Related Keywords

Foster City ,California ,United States ,Ireland ,America ,Complera Eviplera ,Kevin Lofton ,Sofosbuvir Velpatasvir ,Anthony Welters ,European Union ,Immunomedics Inc ,Xilio Therapeutics Inc ,Janssen Sciences Ireland Unlimited Company ,Gilead Sciences ,Merck Co Inc ,Department Of Corrections ,Tmunity Therapeutics Inc ,Gilead Public Affairs Department ,Cymabay Therapeutics Inc ,Drug Administration ,Nasdaq ,Gilead Sciences Stock ,Gilead Sciences Inc ,Merck Sharp Dohme ,Asegua Therapeutics ,Mirobio Ltd ,Liver Disease ,Cymabay Therapeutics ,Gross Margin ,Operating Expenses ,Effective Tax ,Forward Looking Statements ,Opportunistic Infections ,European Economic Area ,Xilio Therapeutics ,Orphan Drug ,New Drug Application ,Prescription Drug User Fee Act ,Annual Meeting ,Lead Independent ,Just Capital ,Private Securities Litigation Reform Act ,Safe Harbor ,Merck Sharp ,Cell Therapy ,Janssen Sciences Ireland Unlimited ,Gilead Sciences Chart ,Ilead Sciences Kurs ,Ilead Sciences Aktie ,